144 related articles for article (PubMed ID: 6203753)
1. A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications.
Monfardini S; Rilke F; Valagussa P; Bajetta E; Canetta R; Buzzoni R; Giardini R; Viviani S
Eur J Cancer Clin Oncol; 1984 May; 20(5):609-17. PubMed ID: 6203753
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the working formulation of non-Hodgkin's lymphoma with the Rappaport, Kiel, and Lukes & Collins classifications. Translational value and prognostic significance based on review of 658 patients treated at a single institution.
Ersbøll J; Schultz HB; Hougaard P; Nissen NI; Hou-Jensen K
Cancer; 1985 May; 55(10):2442-58. PubMed ID: 3986740
[TBL] [Abstract][Full Text] [Related]
3. A new working formulation of non-Hodgkin's lymphomas. A retrospective study of the new NCI classification proposal in comparison to the Rappaport and Kiel classifications.
Krueger GR; Medina JR; Klein HO; Konrads A; Zach J; Rister M; Janik G; Evers KG; Hirano T; Kitamura H; Bedoya VA
Cancer; 1983 Sep; 52(5):833-40. PubMed ID: 6871825
[TBL] [Abstract][Full Text] [Related]
4. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Engelhard M; Brittinger G; Huhn D; Gerhartz HH; Meusers P; Siegert W; Thiel E; Wilmanns W; Aydemir U; Bierwolf S; Griesser H; Tiemann M; Lennert K
Blood; 1997 Apr; 89(7):2291-7. PubMed ID: 9116271
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphomas.
Monfardini S; Tancini G; DeLena M; Villa E; Valagussa P; Bonadonna G
Med Pediatr Oncol; 1977; 3(1):67-74. PubMed ID: 65728
[TBL] [Abstract][Full Text] [Related]
6. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
Laver JH; Mahmoud H; Pick TE; Hutchison RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ
Leuk Lymphoma; 2002 Jan; 43(1):105-9. PubMed ID: 11908712
[TBL] [Abstract][Full Text] [Related]
7. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of stage I and II non-Hodgkin's lymphomas of the head and neck: the value of the working formulation and need for chemotherapy.
Shigematsu N; Kondo M; Mikata A
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1111-8. PubMed ID: 3182343
[TBL] [Abstract][Full Text] [Related]
9. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
[TBL] [Abstract][Full Text] [Related]
10. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases.
Parlier Y; Gorin NC; Najman A; Stachowiak J; Duhamel G
Cancer; 1982 Aug; 50(3):401-9. PubMed ID: 7046899
[TBL] [Abstract][Full Text] [Related]
12. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
Laver JH; Mahmoud H; Pick TE; Hutchinson RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ;
Leuk Lymphoma; 2001 Jul; 42(3):399-405. PubMed ID: 11699405
[TBL] [Abstract][Full Text] [Related]
13. [Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].
Parlier Y; Gorin NC; Stachowiak J; Najman A; Duhamel G
Sem Hop; 1981 Nov 8-25; 57(41-42):1685-90. PubMed ID: 6272402
[TBL] [Abstract][Full Text] [Related]
14. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy in non-Hodgkin's lymphomas (author's transl)].
Schmidt CG
Strahlentherapie; 1977 May; 153(5):283-92. PubMed ID: 69343
[TBL] [Abstract][Full Text] [Related]
16. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
[TBL] [Abstract][Full Text] [Related]
17. Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas.
Bonadonna G; Monfardini S; Villa E
Cancer Treat Rep; 1977 Sep; 61(6):1117-23. PubMed ID: 71209
[TBL] [Abstract][Full Text] [Related]
18. A clinico-pathological and immunological study of unfavourable non-Hodgkin lymphomas. Comparison of the Rappaport and Kiel classifications.
Lindemalm C; Christensson B; Johansson B; Mellstedt H; Ost A; Biberfeld P
Acta Pathol Microbiol Immunol Scand A; 1983 Nov; 91(6):435-43. PubMed ID: 6364692
[TBL] [Abstract][Full Text] [Related]
19. The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications.
Garvin AJ; Simon R; Young RC; DeVita VT; Berard CW
Semin Oncol; 1980 Sep; 7(3):234-43. PubMed ID: 6998002
[TBL] [Abstract][Full Text] [Related]
20. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
